Abbott Can't Escape FCA Suit Over Drug Marketing, Kickbacks

Law360, New York (January 31, 2014, 5:03 PM EST) -- A Pennsylvania federal judge refused Thursday to dismiss a former Abbott Laboratories employee’s suit claiming the company submitted false claims to government health programs by pushing its cholesterol drug TriCor for off-label uses and paying kickbacks to physicians.

In a 50-page memorandum, U.S. District Judge C. Darnell Jones II said that relator Amy Bergman “provides myriad details of Abbott’s marketing statements that contradict its FDA-approved label,” rejecting Abbott’s argument that the allegations of its False Claims Act violations are not specific enough to proceed.

Bergman, a...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

BERGMAN v. ABBOTT LABORATORIES


Case Number

2:09-cv-04264

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Other Statutory Actions

Judge

C. DARNELL JONES, II

Date Filed

September 18, 2009

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.